Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics / Mohammad Mahmoudian, Hadi Valizadeh, Raimar Löbenberg, Parvin Zakeri-Milani
Abstract Aim Nano drug delivery systems can provide the opportunity to reduce side effects and improve the therapeutic aspect of a variety of drugs. Bortezomib (BTZ) is a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. Severe side effects of BTZ are the major dose-limiting factor. Particulate drug delivery systems for BTZ are polymeric and lipidic drug delivery systems. This review focussed on lipidic-nano drug delivery systems (LNDDSs) for the delivery of BTZ. Results LNDDSs including liposomes, solid lipid nanoparticles, and self-nanoemulsifying drug delivery systems showed reduce systemic side effects, improved therapeutic efficacy, and increased intestinal absorption. Besides LNDDSs were used to target-delivery of BTZ to cancer. Conclusion Overall, LNDDSs can be considered as a novel delivery system for BTZ to resolve the treatment-associated restrictions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - 38(2021), 3, Seite 192-202 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mahmoudian, Mohammad [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Bortezomib |
|---|
| Umfang: |
1 Online-Ressource (11 p) |
|---|
| doi: |
10.1080/02652048.2021.1876175 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL01111617X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL01111617X | ||
| 003 | DE-627 | ||
| 005 | 20231109210011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2021.1876175 |2 doi | |
| 035 | |a (DE-627)KFL01111617X | ||
| 035 | |a (KFL)prod_LgpH_10.1080/02652048.2021.1876175 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Mahmoudian, Mohammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics |c Mohammad Mahmoudian, Hadi Valizadeh, Raimar Löbenberg, Parvin Zakeri-Milani |
| 264 | 1 | |c 2021 | |
| 300 | |a 1 Online-Ressource (11 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Aim Nano drug delivery systems can provide the opportunity to reduce side effects and improve the therapeutic aspect of a variety of drugs. Bortezomib (BTZ) is a proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma. Severe side effects of BTZ are the major dose-limiting factor. Particulate drug delivery systems for BTZ are polymeric and lipidic drug delivery systems. This review focussed on lipidic-nano drug delivery systems (LNDDSs) for the delivery of BTZ. Results LNDDSs including liposomes, solid lipid nanoparticles, and self-nanoemulsifying drug delivery systems showed reduce systemic side effects, improved therapeutic efficacy, and increased intestinal absorption. Besides LNDDSs were used to target-delivery of BTZ to cancer. Conclusion Overall, LNDDSs can be considered as a novel delivery system for BTZ to resolve the treatment-associated restrictions | ||
| 653 | |a Bortezomib | ||
| 653 | |a liposomes | ||
| 653 | |a solid lipid nanoparticles | ||
| 653 | |a self-nanoemulsifying drug delivery systems | ||
| 653 | |a formulation | ||
| 653 | |a pharmacokinetics | ||
| 700 | 1 | |a Valizadeh, Hadi |e verfasserin |4 aut | |
| 700 | 1 | |a Löbenberg, Raimar |e verfasserin |4 aut | |
| 700 | 1 | |a Zakeri-Milani, Parvin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d Abingdon : Taylor & Francis Group, 1984 |g 38(2021), 3, Seite 192-202 |h Online-Ressource |w (DE-627)KFL000005967 |w (DE-600)1491079-2 |w (DE-576)079719244 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2021 |g number:3 |g pages:192-202 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/02652048.2021.1876175 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2021 |e 3 |h 192-202 | ||